Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...
The Canadian Press on MSN3h
Canadian scientist wins Breakthrough Prize for discovery of hormone used in Ozempic, MounjaroA Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...
Live Science on MSN3h
$3 million Breakthrough Prize awarded to developers of Ozempic-style drugsFive researchers have been jointly awarded one of this year's Breakthrough Prizes in Life Sciences for their contributions to the development of Ozempic-style drugs.
Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their ...
Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
News-Medical.Net on MSN4d
Rare sugars curb appetite and mimic diabetes drugs in miceRare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in ...
At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...
New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback